3D InSight™ | 3D In Vitro Oncology and Immunology Platform
Uncover valuable insights into mechanisms of action and the effect of multiple cell types in Oncology and Immunology by using our physiologically relevant and scalable 3D Human tumor models.
NEW: 3D InSight™ Patient-derived Primary Tumor Spheroid Platform
Transform your therapeutic development by incorporating patient heterogeneity early on in your drug discovery platform
Our 3D InSight™ Patient-derived Primary Tumor Spheroid Platform revolutionizes preclinical oncology by accurately mirroring patient-specific genomic diversity, complexity of the tumor microenvironment and clinically relevant drug responsiveness - transforming in vitro modeling into predictive insights that align seamlessly with in vivo patient outcomes.
Built on the foundation of InSphero’s expertise with primary tissue models and scalable platforms, these models offer predictive, robust, and reproducible results for informed decision-making.
Why it matters?
All preclinical models, from cell lines to patient-derived xenografts (PDXs) serve a purpose in the spectrum of early discovery. However, they all fail to capture the intra- and inter-tumor complexity of tumors in vivo. Our patient-derived primary tumor spheroids overcome these limitations by:
- Maintaining the original composition of the tumor, including epithelial immune and stromal components
- Reflecting patient-specific heterogeneity and therapeutic responses
- Supporting robust, high-throughput drug screening in Akura™ 96- and 384-well plate formats
Unlock the full potential of your oncology research
Physiological and Biological Relevance
Patient-derived tumor spheroids retain the architecture and complexity of the original tumor tissue, as confirmed by immunohistochemistry (IHC) for all resident cell populations. This ensures physiological and biological relevance for drug screening applications.
Industry-Grade
Scalability
Therapeutic testing across multiple patient-derived tumor spheroids using automation-compatible Akura™ 96 and 384 well plates with high-dimensional, high throughput readouts.
Proven
Reproducibility
Consistent composition and size of Patient-derived Primary tumor spheroids enable robust and reproducible therapeutic screening across oncology applications.
Bring confidence to your oncology pipeline with 3D in vitro models that reflect real patient biology
3D Tumor Models for Advanced 3D In Vitro Oncology and Immunology Research
Conventional, 2D-monolayer cell line-derived tumor models produce generic oncology readouts for viability. The outdated flat biology, which is not representative of tumor and patient heterogeneity is unable to fully capture the unpredictable progression of a complex disease like cancer.
Our 3D InSight™ Oncology platform provides human-derived 3D tumor models that enable you to study cellular interaction in a 3D environment. Our technology enhances the ability to assess various phenotypic characteristics that can accurately predict different aspects of in vivo biology.
Our scalable, reliable and reproducible 3D tumor models allow you to study intracellular interactions and the effect of the tumor micro environment (TME) on therapeutic resistance and susceptibility. Our ability to multiplex imaging, biochemical and morphological read outs ensure that you maximize the information you get out of a single tumor spheroid in the context of its TME. Our platform is compatible with many therapeutic modalities including but not limited to small molecules, biologics, protein therapeutics and siRNAs. Each modality is validated on the 3D InSight ™ tumor spheroid platform for biological and technical activity.
Why 3D In Vitro Oncology and Immunology with InSphero?
Human 3D tumor models are the future of cancer research
Scalable, industry-ready 3D in vitro tumor spheroids
Enhance your drug investigation by using our scalable 3D InSight™ Oncology & Immunology platform, reproducing the complex tumor micro-environment.
Monitoring the immune component in cancer biology
Make early-stage go/no-go decisions
Our Approach in 3D In Vitro Oncology and Immunology
Target Identification and Validation
Modeling tumor heterogeneity and patient diversity
High throughput screening
